We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

By LabMedica International staff writers
Posted on 19 May 2025

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. More...

However, more than 90% of physician offices in the U.S. lack the necessary infrastructure to perform on-site CBC testing, often resulting in delayed results and missed diagnostic opportunities during patient consultations. Now, a new cartridge-based CBC test is expanding access to quick results in physician offices, pharmacies, and home care settings, making data-driven diagnostics more accessible.

CytoChip’s (Irvine, CA, USA) CitoCBC is a cartridge-based CBC system that allows healthcare professionals to quickly perform accurate CBC testing not only in hospitals but also in physician offices, pharmacies, nursing homes, and other places where CBC testing was previously unavailable. CitoCBC is designed to offer both ease of use and high performance. The self-contained cartridge simplifies the testing process, providing a comprehensive 5-part differential CBC with a turnaround time of just eight minutes. On-screen, step-by-step instructions guide users through the process, even if they have no laboratory experience. The system includes advanced features, such as Optical Fluorescent Platelet (OFP) detection, which surpasses the capabilities of many traditional lab analyzers. The analyzer also conducts periodic self-checks to ensure its functionality. Test results can be displayed on-screen, printed out, or transmitted via connection to a laboratory information system (LIS). In comparisons to state-of-the-art CBC solutions used in hospitals and clinical labs, the performance of CitoCBC has proven to be substantially equivalent. The CBC counts produced meet the rigorous CLIA 2024 Proficient Testing standards for hematology.

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance and a CLIA Waiver for CitoCBC, making it the first cartridge-based CBC test to achieve this milestone. This breakthrough significantly increases access to CBC testing in decentralized healthcare environments like physician offices, pharmacies, and home care settings. The CLIA Waiver eliminates testing barriers, allowing for fast, reliable CBC results in a compact device, which ultimately improves patient care and supports better clinical decision-making. With FDA clearance and a CLIA waiver, CitoCBC ensures accuracy and reliability, allowing non-laboratory personnel to operate the system effectively. Overall, CitoCBC provides state-of-the-art testing with a small footprint, requiring minimal staff training and lower capital investment. The product will first launch in the United States and later expand to select European countries upon obtaining the CE Marking.

"Achieving CLIA Waiver for a CBC test is a major step forward in improving access to diagnostics at the point of care," said Dr. Wendian Shi, CEO of CytoChip. "This milestone not only fills a critical gap among CLIA Waived testing but also expands diagnostic accessibility in underserved areas."

Related Links:
CytoChip


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.